Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1626
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17431499 | USE OF SPIROPIDION | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 19347194 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Final Rejection | SK CHEMICALS Co., Ltd. |
| 17593842 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Non-Final OA | SK CHEMICALS CO., LTD. |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18567504 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | Non-Final OA | Katholieke Universiteit Leuven |
| 17769858 | Lipid and Lipid Nanoparticle Formulation for Drug Delivery | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18565742 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS | Non-Final OA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH |
| 18437859 | TREATING FIBROSIS WITH A CCK RECEPTOR INHIBITOR | Final Rejection | GEORGETOWN UNIVERSITY |
| 17612989 | PHARMACEUTICAL COMBINATION | Non-Final OA | Agency for Science, Technology and Research |
| 18453156 | CDK2 DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 17439668 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Non-Final OA | ATROGI AB |
| 18000586 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEAD LICE | Non-Final OA | CReDO Science, LLC |
| 17860539 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Final Rejection | HARMONY BIOSCIENCES, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy